Precision public health focuses on populations and uses genetic testing to assess presumably healthy people without identified personal or family history of heritable disease or suboptimal response to drugs. The goals include early identification of health risks and modification of preventive care approaches, as well as safer and more effective medication use. Panelists Jeffrey A. Shaman, from Coriell Life Sciences, and Adam Buchanan from Geisinger, will share their experiences implementing precision public health from the perspectives of a large self-insured employer, a health system, and a retirement system. These organizations have focused on returning medically actionable results that impact both disease and medication management. We will discuss the barriers and facilitators to implementation, as well as evidence of program impact. The conversation is intended to help decision-makers evaluate the business case for supporting genetic testing in groups such as employees, retirees, and members of health systems.